Abstract
As dementia is a fast-growing health care problem, it is becoming an increasingly urgent need to provide an early diagnosis in order to offer patients the best medical treatment and care. Validated biomarkers which reflect the pathology and disease progression are essential for diagnosis and are important when developing new therapies. Today, the core protein biomarkers amyloid-β42, total tau and phosphorylated tau in the cerebrospinal fluid (CSF) are used to diagnose Alzheimer's disease (AD), because these biomarkers have shown to reflect the underlying amyloid and tau pathology. However, the biomarkers have proved insufficient predictors of dementias with a different pathology, e.g. frontotemporal dementia (FTD); furthermore, the biomarkers are not useful for early AD diagnosis. Familial dementias with a known disease-causing mutation can be extremely valuable to study; yet the biomarker profiles in patients with familial dementias are not clear. This review summarizes CSF biomarker findings from studies on symptomatic and presymptomatic individuals carrying a mutation in one of the genes known to cause early-onset familial AD or FTD. In conclusion, the biomarker profile of inherited AD is quite similar between carriers of different mutations as well as similar to the profile found in sporadic AD, whereas familial FTD does not seem to have a clear biomarker profile. Hence, new biomarkers are needed for FTD.
| Original language | English |
|---|---|
| Journal | Dementia and Geriatric Cognitive Disorders |
| Volume | 40 |
| Issue number | 1-2 |
| Pages (from-to) | 54-62 |
| Number of pages | 9 |
| ISSN | 1420-8008 |
| DOIs | |
| Publication status | Published - 22 Jul 2015 |
Keywords
- Alzheimer Disease
- Amyloid beta-Peptides
- Biomarkers
- Early Diagnosis
- Frontotemporal Dementia
- Humans
- Mutation
- tau Proteins